ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5309ometendo-5309Research ArticleСтатьиArticlesЭффект Диабетона МВ на параметры углеводного обмена, массу тела, а также уровни адипонектина, интерлейкина-6 и фактора некроза опухолей альфа у пациентов с сахарным диабетом 2 типаEffekt Diabetona MV na parametry uglevodnogo obmena, massu tela, a takzhe urovni adiponektina, interleykina-6 i faktora nekroza opukholey al'fa u patsientov s sakharnym diabetom 2 tipaPigarovaE Akpigarova@gmail.com20111512201184№4 (2011)6061Copyright © Pigarova E.A., 20112011Pigarova E.A.Pigarova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5309ReferencesAshcroft F.M., Gribble F.M. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels // J Diabetes Complications. - 2000 Jul-Aug. - № 14(4). - Р. 192-6.Ashcroft F.M., Gribble F.M. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels // J Diabetes Complications. - 2000 Jul-Aug. - № 14(4). - Р. 192-6.Drouin P., Standl E., Diamicron M.R. Study Group. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes // Diabetes Obes Metab. - 2004 Nov. - № 6(6). - Р. 414-21.Drouin P., Standl E., Diamicron M.R. Study Group. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes // Diabetes Obes Metab. - 2004 Nov. - № 6(6). - Р. 414-21.Drouin P. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study // J Diabetes Complications. - 2000 Jul-Aug. - № 14(4). - Р. 185-91.Drouin P. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study // J Diabetes Complications. - 2000 Jul-Aug. - № 14(4). - Р. 185-91.Drzewoski J., Zurawska-Klis M. Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus // Curr Med Res Opin. - 2006 Oct. - № 22(10). - Р. 1921-6.Drzewoski J., Zurawska-Klis M. Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus // Curr Med Res Opin. - 2006 Oct. - № 22(10). - Р. 1921-6.Frey N., Laveille C., Paraire M., Francillard M., Holford N.H., Jochemsen R. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation // Br J Clin Pharmacol. - 2003 Feb. - № 55(2). - Р. 147-57.Frey N., Laveille C., Paraire M., Francillard M., Holford N.H., Jochemsen R. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation // Br J Clin Pharmacol. - 2003 Feb. - № 55(2). - Р. 147-57.Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes) // Diabetes Obes Metab. - 2005 Nov. - № 7(6). - Р. 722-8.Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes) // Diabetes Obes Metab. - 2005 Nov. - № 7(6). - Р. 722-8.Maddock H.L., Siedlecka S.M., Yellon D.M. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide // Cardiovasc Drugs Ther. - 2004 Mar. - № 18(2). - Р. 113-9.Maddock H.L., Siedlecka S.M., Yellon D.M. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide // Cardiovasc Drugs Ther. - 2004 Mar. - № 18(2). - Р. 113-9.McGavin J.K., Perry C.M., Goa K.L. Gliclazide modified release // Drugs. - 2002. - № 62(9). - Р. 1357-64.McGavin J.K., Perry C.M., Goa K.L. Gliclazide modified release // Drugs. - 2002. - № 62(9). - Р. 1357-64.Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G.E., Shaw K.M. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients // Eur J Clin Invest. - 2004 Aug. - № 34(8). - Р. 535-42.Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G.E., Shaw K.M. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients // Eur J Clin Invest. - 2004 Aug. - № 34(8). - Р. 535-42.Tessier D., Dawson K., Tétrault J.P., Bravo G., Meneilly G.S. Glibenclamide vs gliclazide in type 2 diabetes of the elderly // Diabet Med. - 1994 Dec. - № 11(10). - Р. 974-80.Tessier D., Dawson K., Tétrault J.P., Bravo G., Meneilly G.S. Glibenclamide vs gliclazide in type 2 diabetes of the elderly // Diabet Med. - 1994 Dec. - № 11(10). - Р. 974-80.Van Staa T., Abenhaim L., Monette J. Rates of hypoglycemia in users of sulfonylureas // J Clin Epidemiol. - 1997 Jun. - № 50(6). - Р. 735-41.Van Staa T., Abenhaim L., Monette J. Rates of hypoglycemia in users of sulfonylureas // J Clin Epidemiol. - 1997 Jun. - № 50(6). - Р. 735-41.
The authors declare that there are no conflicts of interest present.